Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.57 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299490 | 1.00 | CYP19A1 (0.61) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL6173273 | 0.85 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6299346 | 0.85 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL9371997 | 0.83 | CYP11B1 (0.53) | CYP19A1CYP11B1 | |
| SCHEMBL10932073 | 0.80 | CYP19A1 (0.73) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL28739413 | 0.78 | CYP19A1 (0.57) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL28544018 | 0.78 | HMOX1 (0.64) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL29669857 | 0.78 | HMOX1 (0.64) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL11276326 | 0.78 | ADRA2C (0.63) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C | |
| SCHEMBL29669801 | 0.78 | CYP19A1 (0.57) | CYP19A1HMOX1CYP51A1CYP11B1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | CYP19A1 962/4885HMOX1 2641/4885CYP51A1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.